CEBPZ and acute myeloid leukemia: In the subset of CBF-AML patients with a suboptimal molecular response (baseline fusion transcripts ≥0.1% after Induction 1), the azacitidine group showed a significantly higher EFS and a lower CIR compared to the observation group.